Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business OfficerRead More
In June 2017, JSR Life Sciences acquired Selexis as part of JSR’s commitment to offer industry partners best-in-class contract development manufacturing (CDMO) services. Selexis SA and KBI Biopharma, which was acquired by JSR in 2015, have joined forces to provide industry partners “GENE to GMP in 9 Months” — the most robust and fastest service offering for the biopharmaceutical industry.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2021 Selexis SA. All Rights Reserved.